Abstract In this study, we explored the structural requirements of known estrogen receptor modulators for biological activity using pharmacoinformatics approaches to elucidate critical functionalities for new, potent and less toxic chemical agents for successful application in estrogen therapy. For this purpose, a group of nonsteroidal ligands 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide derivatives were collected from the literature to perform quantitative structure-activity relationship (QSAR), pharmacophore and molecular docking studies. = 0.769, s pb = 0.336) revealed the importance of HB donor and hydrophobic features for both subtypes, whereas HB acceptor and aromatic ring were critical for aand b-subtypes, respectively. The functionalities developed in the QSAR and pharmacophore studies were substantiated by molecular docking studies which provided the preferred orientation of ligands for effective interaction at the active site cavity.
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Introduction
Estrogens are sex steroid hormones, secreted by the ovaries and testis, and control a number of physiological actions including the development of female reproductive system and secondary characteristics, neuroendocrine actions involved in the control of ovulation, the cyclic preparation of the reproductive tract for fertilization and implantation, and major actions on mineral, carbohydrate, protein and lipid metabolism (Lewis and Jordan, 2005) . These hormones also demonstrate remarkable effectiveness in deterrence and management of pre-and postmenopausal diseases (Rossouw et al., 2002; Yaffe et al., 1998) . Hormone replacement therapy (HRT) is well known as one of the most common uses of estrogen agonists where synthetic estrogens are administered to reduce osteoporotic fractures and improve menopausal symptoms (Rossouw et al., 2002) . However, HRT increases the risk of breast and uterine cancers (Chlebowski et al., 2003; Gehrig et al., 2004) . The most common uses of estrogen agonists are in HRT and contraception, while estrogen antagonists are used in the treatment of hormone-responsive breast cancer and female infertility (Clarke et al., 2003) .
The biochemical basis of estrogen actions is thought be primarily via the regulation of gene expression after binding to estrogen receptor (ER), which belongs to the nuclear receptor superfamily. It is often overexpressed in the tissue of breast cancer patients, which promotes the estrogen-dependent proliferation of cancer cells (Doisneau-Sixou et al., 2003; Foster et al., 2001a, b; Holst et al., 2007) . The nuclear receptor family members share a conserved structural architecture consisting of six structural domains, including ligand binding domain (LBD) . The orientation of helix 12, located at the carboxy-terminus of the LBD, is fundamental in distinguishing between agonists and antagonists (Pike et al., 2000) . There are two subtypes of ER, namely ERa and ERb that quite similar in overall structure. ERa is expressed predominantly in breast and uterine tissues, whereas ERb is found chiefly in the brain, bone and vascular epithelium (Gustafsson, 1999) .
Selective estrogen receptor modulators (SERMs) are structurally diverse molecules which exhibit a unique pharmacological profile. Depending upon the target tissues, SERMs are characterized by estrogen agonist action in some tissues but as estrogen antagonists in others (Maximov et al., 2013; Riggs and Hartmann 2003) . The agonist and antagonist properties of SERMs arise from differentially expressed ERs due to ligand-dependent receptor conformational deviations, interactions with various co-activators and co-repressors and following changes in gene transcription (Pickar et al., 2010) . Tamoxifen, raloxifene, toremifene, etc., are potent SERMs that have been used to treat breast cancer and osteoporosis (Chmel et al., 2002; Fisher et al.,1998 Fisher et al., , 2005 . Successful SERMs are classified in generations, suggesting a progressive development in a process intended to improve the beneficial effects while reducing the harmful side effects associated with the earlier SERMs (Dowers et al., 2006) .
The use of pharmacoinformatics computational approaches in the pharmaceutical industry is a very popular and useful application to search for potent and safe lead molecules. The traditional method of drug discovery is a complex process and takes about 15 years of time and is estimated to cost $0.8 to $1 billion to launch a drug into the market (Dalkas et al., 2012) . It is reported that out of 5000 lead compounds, only 5 may enter into the preclinical phase and then to approval for human testing, ultimately (Dalkas et al., 2012) . This clearly indicates that the traditional approaches are cost-intensive and time-consuming, necessitating alternative approaches to save money, time and effort. The use of pharmacoinformatics techniques in drug discovery and development is rapidly gaining in popularity, implementation and appreciation (Kapetanovic, 2008) . The proper application of this technique can develop molecules with optimal efficacy. Keeping in mind the objective of immense utility of SERMs for the treatment of postmenopausal diseases, researchers in academia as well as in industry are dedicated to the development of synthetic therapeutic SERMs for estrogen therapy (Brogia et al., 2013; Chang et al., 2013; Lewis et al., 1995; Mukherjee et al., 2005; Smith et al., 2007; Zhang et al., 2013) . Pharmacoinformatics techniques, ligand-based approaches such as 2D/3D quantitative structure activity relationship (QSAR) and pharmacophore mapping, and structure-based molecular docking method have become vital tools (Verma et al., 2010) for this purpose.
In the present study, a series of 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide derivatives (Wang et al., 2012) , reported as promising SERMs (Wang et al., 2012) for estrogen therapy, were evaluated with their relative binding affinity for pharmacoinformatics studies to explore the physicochemical properties and 3D structural conformation of chemical moieties for selective estrogenic actions, through both 2D QSAR and pharmacophore studies. The QSAR modeling was carried out to obtained statistical validated models useful in exploring structure activity relationship (SAR) of the compounds, while pharmacophore concept was based on the type of interactions observed in the molecular recognition and alternatively can be used as a query in a 3D database search to identify new structural classes of potential lead compounds and also can serve as a template for generating alignment for 3D QSAR analysis.
Materials and methods
Pharmacoinformatics models were derived from a congeneric dataset of 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide derivatives (Wang et al., 2012) (Table 1) to explore QSAR and pharmacophore modeling studies to determine pharmacophoric features of the small molecule required for binding affinity of ER subtypes. The most active compounds of both a-and bsubtypes are depicted in Fig. 1 . The relative binding affinity (RBA) of the of the dataset was converted into kRBA = log(1000 9 RBA) for QSAR study, while for pharmacophore modeling study it was expressed as pRBA = 1/RBA. The primary goal of the study was to generate a statistical relationship between the structure and corresponding activity, and deduce a pharmacophore map through receptor-independent space modeling techniques. Furthermore the functionalities derived in the receptor-independent studies were correlated with binding interactions observed between most active compounds of both a-and b-subtypes in the active site cavity of ER. The dataset (Table 1) was randomly divided into training set (n tr = 22) and test set (n ts = 10) for model generation and validation of generated models, respectively.
The different statistical parameters considered to judge the models were correlation coefficient (R 2 ), standard error of estimation (se), leave-one out (LOO) cross-validated correlation coefficient (Q 2 ) and modified correlation coefficient (r m 2 ). Additionally, the variance ratio (F) with degree of freedom (df) and explained variance (EV) for 2D-QSAR study were also considered, while different cost factors (Islam et al., 2008) were used for space modeling ) of the test set were also determined in both studies.
QSAR study
QSAR is the mathematical relationship and statistically validated model which attempts to find a statistically significant correlation between chemical structure and biological activity using chemometric techniques. In drug discovery and design research, structure denotes the properties or descriptors of the molecules, their substituents or interaction energy fields, while biological activity refers to an experimental biological/biochemical endpoint such as binding affinity, toxicity or rate constants, while chemometric methods include MLR, PLS, PCA, PCR, ANN, GA, etc. Various QSAR approaches have been developed gradually over a time span of more than a hundred years and have served as a valuable predictive tool, particularly in the design of pharmaceuticals and agrochemicals. The methods have evolved from Hansch and Free-Wilson's (Kubinyi, 2004) one-or two-dimensional linear free-energy relationships, via Crammer's three-dimensional QSAR (Cramer et al., 1988 ) to Hopfinger's fourth (Hopfinger and Tokarski, 1997 ) and Vedani's fifth and sixth dimensions (Vedani and Dobler, 2002) . One-and two-dimensional and related methods are commonly referred to as 'classical' QSAR methodologies. Irrespective of the type, all QSAR formalisms presume that every molecule included in the study binds to the same site of the same target receptor. However, the main difference between all these formalisms reside in the manner in which each one of them treats and represents structural properties of the molecules and extracts the quantitative relationships between the properties and activities.
The molecular descriptors were generated using molecular orbital environment (MOE) tool developed by Chemical Computing Group (MOE, 2007) [35, 36][35, 36] . The compounds of the dataset were minimized using MMFF94 force field. The minimization algorithm used was the steepest descent followed by conjugate gradient method until it reached RMS gradient of 0.001 kcal/mol/Å . The QuaSAR module of MOE was considered for descriptors generation. More than 210 descriptors were obtained in this series of compound for QSAR study. All descriptors calculated in the MOE could be categorized into three classes: The 2D descriptors are only based on atoms and connection information of the molecule for the calculation; i3D descriptors use 3D coordinate information about each molecule; however, they are invariant to rotations and translations of the conformation; and x3D descriptors known as external 3D descriptors are based on 3D coordinate information but also require an absolute frame of reference.
In order to obtain robust and good predictive models by predominant descriptors affecting binding affinity of the training set compounds, standard and forward stepwise methods of Statistica (http://www.statsoft.com) were used, considering descriptors as independent variable and kRBA as dependent variable. The descriptors with constant or near-constant values were deleted, and also in order to minimize redundant information, auto-correlated ([0.5) descriptors were not considered in the model generation.
Pharmacophore space modeling study
The HypoGen algorithm in Discovery Studio (Accelrys, 2013) was used to generate pharmacophore model for both a-and b-subtypes of ER ligands. Pharmacophore hypothesis can visualize potential interactions between ligand and active site of the receptor molecule. A pharmacophore is a set of functional group or fragment type in a spatial arrangement that represents the interaction made in common by a set of small molecular ligands with a protein receptor. The conformational models were generated for each ligand to ensure good coverage of conformational space within the minimum number of conformers.
The pharmacophore concept is based on the kinds of interaction observed in molecular recognition, i.e., hydrogen bonding, charge, and hydrophobic interaction. In order to obtain the pharmacophore hypothesis, conformational models were generated for each ligand using algorithm, out of two, i.e., fast and best (Kristam et al., 2005) . This was followed by the conformer generation, an algorithm which also considers chemical features and conformers, and operates in two modes: HipHop and HypoGen. The HipHop generates pharmacophore models using active compounds only, whereas the HypoGen takes activity data into account and uses both active and inactive compounds in an attempt to identify a hypothesis that is common among the active compounds but not in the inactive compounds (Kristam et al., 2005) . It builds top ten scoring hypothesis models with considering the training set, conformational models and chemical features by three steps: a constructive step, a subtractive step and an optimization step (Sadler et al., 1998) . The constructive step generates hypotheses that are common among the most active compounds. In subtractive step, the hypotheses that fit to the inactive compounds are removed. Finally, the optimization step attempts to improve the score of the remaining hypotheses by applying small perturbation (Kristam et al., 2005; Li et al., 2000) .
Validation of QSAR and pharmacophore models
Validation is an essential step of any pharmacoinformatics model to judge the predictivity and applicability as well as robustness. In the current study, both QSAR and pharmacophore models were validated by internal validation and test set prediction. Further the pharmacophore models were validated by cost function analysis and Fischer's randomization test.
Internal validation
The best models of both studies were validated internally using leave-one out (LOO) cross-validation method. In this procedure, randomly one compound was deleted from training set in each cycle and model regenerated using rest of the compounds with same parameters used in original model. The new generated model was used to predict the activity of deleted compound. The procedure was continued until all molecules of the training set deleted and activity predicted. The Q 2 and se were calculated based on predicted activity of training compounds. High Q 2 ([0.5) and low se (\0.5) explained better predictive ability of the model (Kubinyi et al., 1998) . Further to confirm the good predictive ability of the training set compounds, r m 2 developed by Roy et al. (Ojha et al., 2011; Roy et al., 2012) was calculated. The r m 2 is a measure of the degree of deviation of the predicted activity from the observed ones.
It is reported that model may be considered with r m
] suggested by (Golbraikh and Tropsha, 2002) , was also calculated. It is reported that the value of the parameter less than 0.1 explained good predictive ability and robustness of the model. The R 2 and R 0 2 are the correlation coefficient between predicted versus observed activities for regressions with intercept and without intercept (through the origin), respectively.
Test set prediction
The prediction of test set compounds is a crucial step in order to verify whether selected model was able to accurately predict the activities of compound beyond the training set molecule. External validation provides the ultimate proof of the true predictivity of the model, and the predictive capacity of the model was judged best on statistical parameters, R pred 2 and s p . The threshold value of R pred 2 is C 0.5, whereas for s p it is B0.5 (Golbraikh and Tropsha, 2002; Mitra et al., 2010) . The value of R pred 2 depends on the mean observed activity of the training set compounds. Consequently high values of this parameter may be obtained for compounds with a wide range of activity data, but this may not indicate that the predicted activity values are very close to those observed. Though a good overall correlation is maintained, there may be a significant numerical difference between the two values. To better indicate the predictive ability of the model, modified r 2 [r m(test) 2 ] (Roy et al., 2009; Roy and Roy, 2008) values were calculated and threshold value is reported as 0.5.
Cost function analysis
The statistical parameters employed for hypothesis generation were spacing, uncertainty and weight variation. Spacing is a parameter representing the minimum inter-features distance that may be allowed in the resulting hypothesis. The weight variation is the level of magnitude explored by the hypothesis where each feature signifies some degree of magnitude of the compound's activity. This is varied in some cases from 1 to 2. In other cases, the default value of 0.3 is generally considered. The uncertainty parameter reflects the error of prediction and denotes the standard deviation of a prediction error factor called the error cost. In the present work, values of 1.5 to 3.0 were considered as the uncertainty parameter. The total cost function is minimized encompassing three terms, viz., weight cost, error cost, and configuration cost. Weight cost is value that increases as the weight variation in the model deviates from input weight variation value. The deviation between the estimated activity of the molecule in the training set and their experimentally determined value is the error cost. A fixed cost depends on the complexity of the hypothesis space being optimized and is also denoted as the configuration cost. The configuration cost is equal to the entropy of hypothesis space and should have a value \17 for a good pharmacophore model. In the selected models of both a-and b-subtypes, the configuration cost was found less than 15. The HypoGen algorithm also calculates the cost of a null hypothesis that assumes no relationship in the data, and the experimental activities are normally distributed about their mean. Accordingly, the greater the difference (Dcost) between the total and the null costs, it is more likely that the hypothesis does not reflect a chance correlation.
Fischer's randomization test
The Fischer's randomization test was used to ensure strong correlation between the chemical structures and the biological activity of the training set molecule. In this method, the biological activity was scrambled assigning them new values. After that, the pharmacophore hypotheses were generated using the same features and parameters as those used to develop the original pharmacophore hypotheses. If the randomization run generates better correlation coefficient and/or better statistical parameters than the original hypothesis, this may be considered to be developed by chance. Depending upon the statistical significance, randomization run produces different number of spreadsheets. The statistical significance is given by following equation.
where a defined as total number of hypotheses having a total cost lower than best significant hypothesis, whereas b denoted by total number of HypoGen runs and random runs. In case of 95 % confidence level, 19 random spreadsheets are generated (b = 20) and every generated spreadsheet is submitted to HypoGen using the same experimental conditions as the initial run. In the present study, the developed pharmacophore model was checked at 95 % confidence level that produced 19 spreadsheets.
Molecular docking
The molecular docking study was performed by using LigandFit of receptor-ligand interactions protocol in Discovery Studio (Accelrys, 2013) after preparing ligand and receptor. For ligand preparation, all the duplicate structures were removed and ionization change, tautomer generation, isomer generation and Lipinski filter were set to false. In order to prepare receptor, the hydrogen atoms were added to the protein molecules (PDB ID: 3ERT (Shiau et al., 1998) and 2QTU (Richardson et al., 2007) for a-and b-subtypes, respectively), and water molecules were removed. The pH of the protein was set in the range of 6.5-8.5. The active site was selected based on the ligand binding domain of the bound ligand. LigandFit was chosen for receptor-ligand interaction, and PLP1 was selected as the energy grid. The conformational search of the ligand poses was performed by Monte Carlo method with the torsional step size for polar hydrogen set to ten. The docking was performed with consideration of electrostatic energy with maximum internal energy 10,000 Cal. But no attempt was made to minimize the ligand-receptor complex (rigid docking). After completion of docking, the docked enzyme (protein-ligand complex) was analyzed to investigate the type of interactions. Docking conformers of each compound were ranked according to their dock score function.
Results and discussion
QSAR
The QSAR study was performed with the training set molecules of both a-and b-subtypes to obtain statistical relationships between molecular descriptors and binding affinity. The best QSAR models were developed with the contribution of logP(o/w), AM1_LUMO, balabanJ (Table 2 ) and SMR_VSA1 for a-subtype, whereas, E_stain, AM1_dipol, GCUT-SLOGP_0 and GCUT_SMR_1 (Table 2) for b-subtype. The predicted activities based on the both models are shown in Table 3 and Fig. 4 . In order to improve the models, autocorrelated (|r| [ 0.5) descriptors were not considered in the model generation. Stepwise multiple linear regression method of Statistica was adopted to reach in the final model.
a-Subtype
The best statistical model was developed with combination of logP(o/w), AM1_LUMO, balabanJ and SMR_VSA1 descriptors as below. The most important descriptor found in the best model of a-subtype was balabanJ, which is the connectivity topological index and a good descriptor for the shape of the molecule. Its large and positive coefficient in the model indicated that a bigger size and high branching of molecules might be favorable for binding affinity of ER ligands. Despite the fact that examples of QSAR studies based on Balaban index are rare in the literature, a few recent studies (Balaban et al., 2005; Kim et al., 2002; Rastija and MedicSaric, 2009 ) and the present study showed that this index can be successfully used for this purpose. The coefficient of this parameter was found as 4.687 that indicates the superiority of the descriptor in the model. The second most important descriptor was found in the model, logP(o/w) with positive coefficient (0.869). The logP(o/w) is the logarithm value of ratio of the concentration of a chemical in n-octanol to that in water in a two-phase system at equilibrium. This coefficient has been shown to be one of the key parameters in QSAR/QSPR studies (Gupta and Prabhakar, 2008; Platts et al., 2006; Saxena et al., 2003) and measures the hydrophobicity and hydrophilicity of a substance. Its positive regression coefficient in the model suggested that high hydrophobicity of the molecule might be favorable for their ability for membrane penetration and distribution into the organisms along with enhanced hydrophobic interactions at the active site cavity of ER. The third most important parameter found in the model was AM1_LUMO, the energy of the lowest unoccupied molecular orbital (LUMO) calculated using AM1 Hamiltonian. This descriptor reflects electrophilic reactivity and plays an important role in reductive processes in which an electron from a molecular donor anion or metallic surface is assumed to transfer into this orbital on an acceptor molecule (Burrow and Modelli, 2013) . The orbital energy has been successfully used in the development of QSAR models (Kupcewicz et al., 2013; Levet et al., 2013; Nandy et al., 2013; Nantasenamat et al., 2013) . The negative coefficient of this descriptor in the model suggested that highly nucleophile compounds resulted in high binding affinity and might influence binding at the ERa subtype. The least important parameter among four descriptors in the model was SMR_VSA1, i.e., molecular refractivity (including implicit hydrogen). This property is basically sums the approximate exposed surface based on molar refractivity. The positive contribution of this parameter suggested that high molar refractivity value of the molecule was crucial for binding affinity.
b-Subtype
The best model of b-subtype was derived with importance of four parameters, GCUT_SMA_1, GCUT_SLOGP_0, AM1_dipol and E-strain (Table 2) . The most significant parameter was found in the model, GCUT_SMR_1, which is atomic charge contribution to the molar refractivity instead of partial charges. The negative contribution of the descriptor in the model indicated that less atomic refractivity might be influential for the binding affinity. The second most significant descriptor found was GCUT_SLOGP_0, which used atomic contribution to logP (using the Wildman and Crippen SlogP method (Wildman and Crippen, 1999) instead of partial charge. Positive coefficient of this descriptor suggested that high hydrophobicity value enhances the binding affinity as well as strengthens the interaction at the active site cavity. Dipole moment calculated using AM1 Hamiltonian was found crucial for the binding affinity toward b-subtype. This is the magnitude of dipole moments, indicating the strength and orientation behavior of a molecule in an electrostatic field, and it also behaves as a marker for chemical reactivity. The negative contribution of this descriptor indicated that a decrease in the charge density of the molecule might be crucial for binding affinity. The least significant parameter for the model of b-subtype was found to be E_strain. This descriptor is the current energy minus the value of the energy at a near local minimum. The current energy is calculated as for the E-descriptor. The local minima energy is the value of the E-descriptor after first performing an energy minimization. The model suggested that high E_train value of the molecule might be favorable for binding interaction toward ERb.
Pharmacophore
The pharmacophore models were derived from training set (n tr = 22) molecules, whereas test set (n ts = 10) molecules were used to check the predictive ability of the model.
Hypogen algorithm generates ten alternative pharmacophore hypotheses on each run describing the ER binding affinity of training set molecules. The statistical results of the pharmacophore study of both a-and b-subtypes are given in Table 4 . The best model in both subtypes was adjudged in terms of mapped features, cost difference (D cost ), R 2 and se of the generated hypothesis. The predicted activities based on both models are shown in Table 3 and Fig. 4 .
a-Subtype
The best model of a-subtype (Hypo 1, Run Number 14 in Table 4 ) was mapped with most active compound of the dataset and is shown in Fig. 2 . The selected model consists of the spatial arrangement of HB acceptor and aromatic ring along with hydrophobicity pharmacophoric features for binding affinity of the training set molecule. The null cost of all ten hypotheses of run number 14 (Table 4 ) was found to be 449.103, whereas the cost difference was 365.110. The configuration cost of all ten hypotheses of selected run was found to be 15.231 that explained the suitability of the model as it was reported that configuration cost must be less than 17 for attest a good pharmacophore model (Li et al., 2000) . Hypo 1 in run number 14 (Table 4) showed low total cost of 83.993, high cost difference of 365.110, less se value (1.311) and high correlation coefficient of 0.955 between observed and predicted binding affinities of the training set molecules.
The best model of the a-subtype explained that oxygen atom of sulfonic group attached to ring 'C' (Fig. 1a) was crucial for HB acceptor. Rings 'A' and 'C' (Fig. 1a) along with alkyl group attached to ring 'B' (Fig. 1a) were found to be important for imparting hydrophobicity of the molecule. The hydroxyl group attached to ring 'B' was revealed as HB donor and crucial for hydrogen bond interactions with key amino residues at the active site of ERa
b-Subtype
The best model (Hypo 1 of Run number 23 in Table 4 ) in b-subtype was derived with importance of HB donor, hydrophobicity and aromatic ring features. The final model was selected after successive variation of input parameters viz. spacing, uncertainty and weight variation keeping rest parameters as default. It was observed that at spacing 250, uncertainty 1.5 and weight variation 0.5 the maximum R 2 generated by the hypothesis (0.885), gave lower se (1.328) and high cost difference (D cost = 223.170) values. The mapped pharmacophoric features and inter-feature distances are depicted in Fig. 3 .
The selected model suggested that hydroxyl group attached to ring 'A 0 ' (Fig. 1b) was revealed as HB donor. The rings 'B 0 ' and 'C 0 ' were behaved as aromatic ring, whereas methyl group attached to ring 'A 0 ' was crucial for imparting hydrophobicity of the molecule. The best hypotheses of both a-and b-subtypes were validated to nullify overprediction of the bioactivity for inactive compounds through hyporefine. This process considers the steric interaction of the compounds in hypothesis generation, but in the present work steric hindrance was not portrayed in the selected models of both subtypes, and this means that the presence of steric hindrance of the molecules has no direct influence on binding affinity to ER.
Validation of QSAR and pharmacophore models

Internal validation
The activity of the training compounds was predicted using LOO cross-validation method in case of both QSAR and pharmacophore studies of a-and b-subtypes. In QSAR study, the Q 2 was found to be 0.848 and 0.859 for a-and bsubtypes, respectively, whereas se found 0.370 and 0.261, respectively. The r m 2 value was found to be 0.795 and 0.733 for a-and b-subtypes, respectively. In addition to the above, the Golbraikh-Tropsha metric ([(r 2 -r 0 2 )/r 2 ]) (Golbraikh and Tropsha, 2002) was calculated for both subtypes. For a-subtype, it was found to be 0.023, whereas for b-subtype it was 0.007. Values in both subtypes satisfied the criteria (\0.1) explained by Golbraikh and Tropsha (2002) . In case of pharmacophore model, Q 2 was found to be 0.932 and 0.878 for a-and b-subtypes, respectively, along with value of se 1.311 and 1.328 for a-and b-subtypes, respectively. The r m 2 value for pharmacophore models obtained as 0.891 and 0.815 for a-and b-subtypes, respectively. The statistical results (Q 2 and r m 2 [ 0.5) of the both studies explained that selected models were robust in nature.
Test set
The activity of the test compounds was predicted in both QSAR and pharmacophore studies. The correlation (R) between observed and estimated activities of test compounds was 0.933 and 0.920 for a-and b-subtypes, respectively, in QSAR study, whereas in pharmacophore it was 0.930 and 0.893 for a-and b-subtypes, respectively. The R pred 2 also was calculated. In QSAR study, R pred 
Cost function analysis
The statistical parameters employed for hypothesis generation were spacing, uncertainty and weight variation. Best pharmacophore models of both subtypes were developed with value of weight variation of 2.0 and 0.5 for a-and bsubtypes, respectively, while values of 1.5-3.0 were found optimal in case of uncertainty parameter for a-and bsubtypes, respectively. As was explained in the materials and methods, the configuration cost is equal to the entropy of hypothesis space and should have a value\17 for a good pharmacophore model and in the best pharmacophore models of both a-and b-subtypes the configuration cost were found to be \15. It is reported that greater the difference (Dcost) between the total and the null costs, it is more likely that the hypothesis does not reflect a chance correlation. In the current work, the Dcost for a-and bsubtypes was found to be 365.110 and 223.174, respectively, that clearly indicated that both models do not reflect a chance correlation. Above statistical parameters of both models undoubtedly indicated that both models were not by chance (Fig. 4 ).
Fischer's randomization test
The quality of the hypotheses was further adjudged through a cross-validation technique, Fischer's randomization technique (Snedecor and Cochran, 1967) at 99 % confidence level, but none of the hypotheses generated better parameters in comparison with original hypotheses. So the cross-validated validation technique clearly indicates the superiority of the hypotheses consider for binding affinity to ER subtypes.
Binding interactions
The most active compound of both a-subtype (C6 in Table 1 ) and b-subtype (C31 in Table 1 )was considered for molecular docking study to observe the binding interactions between catalytic amino residues and the ligand. The protein receptor molecules (PDB ID: 3ERT and 2QTU for a-and b-subtypes, respectively) were obtained from RSCB Protein Data Bank (Berman et al., 2000) . The LigandFit module of Discovery Studio was used for the study. In both cases, the molecular docking was given ten best poses with binding interactions at the active site cavity. Receptor-ligand complex for both subtypes was selected based on the dock score and number of binding interactions at the active site cavity of ER. The best dock pose of both a-and b-subtypes is depicted in Fig. 5 .
a-Subtype
The molecular docking study of most active compound of a-subtype (Fig. 5a ) revealed that one hydrogen bond formed between Thr347 and oxygen atom of sulfite group present in between rings 'C' and 'D' (Fig. 1a) , while one bump interaction observed with Ala350 with same group. The rings 'A' and 'C' of the ligand (C6) were connected with amino residue Cys530 through a potential hydrogen bond, in addition ring 'B' was formed one bump interaction. Thr347 and Leu525 were found important to connect ring 'C' through bump and hydrogen bond interaction, respectively. The functionalities developed in the QSAR and pharmacophore studies were successfully correlated with binding interactions observed at the active site cavity of ERa. The importance of hydrophobicity, shape of the molecule, orbital energy and atomic refractivity in QSAR study were assessed through hydrogen bonding and bump interaction observed between the ligand and catalytic residues in the active site. The pharmacophore model was suggested that sulfite group of the molecule might be crucial for HB acceptor that is validated by forming interactions of sulfite group with Thr347 and Ala350 amino acids. The hydroxyl group attached to ring 'A' was Fig. 4 Observed and predicted activities as per QSAR and pharmacophore models revealed as HB donor in the ligand-based pharmacophore model justified by the hydrogen bond interaction between Cys530 and same. The alkyl group attached to ring 'A' and phenyl rings 'B' and 'C' were important for imparting hydrophobicity of the molecules, which was successfully validated by interactions formed with Cys530, Thr347 and Leu525.
b-Subtype
The hydroxyl group attached to the ring 'B 0 ' (Fig. 1b ) formed two hydrogen bonds with each of the Glu305 and Arg346 amino residues. The same functional group of ring 'B 0 ' formed one bump interaction with Arg346 residue. The Glu305 residue directly interacted with ring 'B 0 ' via two bump interactions. The hydroxyl group attached to ring 'A 0 ' was connected to His475 via one potential hydrogen bond and one bump interactions. The functional group of ring 'A 0 ' was able to connect Leu476 and Met479 via bump interaction.
The important functionalities derived in the ligandbased QSAR and pharmacophore studies of b-subtype were successfully correlated with binding interactions found between most active compound b-subtype and catalytic residues of ERb. The hydrophobicity, dipole moment, molar refractivity contributed by atoms of the molecule and the energy parameters were found to be critical in the QSAR model judged by the binding interaction observed in molecular docking study. In the pharmacophore study, hydroxyl group attached to ring 'A 0 ' (Fig. 1b) was important for HB donor which was validated by forming hydrogen bond interaction by His475 with the same. Ring 'B 0 ' showed as an aromatic pharmacophoric feature that was validated by bump interactions with Glu305 and Met340 amino residues at the active site cavity of ERb.
Conclusion
The present study examined the structure-activity relationship for nonsteroidal analogs, SERMs that were being evaluated for a number of estrogen-related diseases, and highlighted some of the molecular properties and structural requirement for selective binding affinity to the ER subtypes. The 2D QSAR models were generated to identify descriptors that contributed significant correlation with biological activity, and search for pharmacophoric elements responsible for selective binding affinity to the ER subtypes. The models generated from the dataset were validated by assessing their statistical significance and predictivity. Hydrophobicity in both QSAR and pharmacophore studies was observed to be prime feature for imparting binding affinity. Orbital energy, molar refractivity and dipole moments were revealed critical parameters for binding affinity toward ER. The space modeling study suggested that accumulation of more hydrophobic and nucleophile substituents to the molecules may provide better therapeutic effects for estrogen therapy. The receptor-based molecular docking study successfully correlated the functionality developed in the ligand-based QSAR and pharmacophore modeling. The polar Glu305, Arg346, Thr379, Trp383 and His475 and nonpolar Met340, Leu476, Met479, Leu525 and Leu536 were found to be the catalytic amino residues at the active site cavity of the ER. Crucial functionalities developed in the receptor-independent pharmacoinformatics study can be used to design and synthesize new chemical entities for effective application in estrogen therapy.
